Butterfly Network logo
Butterfly Network BFLY
$ 7.11 -12.81%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

Butterfly Network Income Statement 2025-2011 | BFLY

Brief overview of revenue and earnings at Butterfly Network

This overview is based on financial performance over the past five years. Revenue reported by Butterfly Network was 46.3 million dollars at the beginning of the period and 97.6 million dollars at the end. The total change was +111%, with a CAGR of approximately 16.1%. The pace indicates confident and sustained business growth.

The gross result shifted from −$61.2 million to $45.7 million, or +174.7%. The relationship between sales and direct costs improved over the period. Gross margin moved from −132.4% to 46.9%. Improving gross profitability strengthens the quality of revenue growth.

EBITDA was −$160 million at the beginning and −$79.7 million at the end of the period (+50.3%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −346.6% to −81.7%. The company improved its ability to convert sales into EBITDA.

The net financial result changed from −163 million dollars to −77.1 million dollars. Losses became smaller, but the business remains unprofitable.

Conclusion

The figures do not all move in the same direction. The strongest signals are net-income growth, a stronger gross margin and positive operating leverage. The most visible risks are a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Butterfly Network

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

946 M 766 M 253 M 388 M 1.16 B 120 M - - - - - - - - -

Shares

247 M 212 M 205 M 200 M 174 M 6.06 M - - - - - - - - -

Historical Prices

3.83 3.62 1.23 1.94 6.69 19.8 - - - - - - - - -

Net Income

-77.1 M -72.5 M -134 M -169 M -32.4 M -163 M - - - - - - - - -

Revenue

97.6 M 82.1 M 65.9 M 73.4 M 62.6 M 46.3 M - - - - - - - - -

Cost of Revenue

51.9 M 33.2 M 49 M 33.9 M 45.5 M 107 M 48.5 M - - - - - - - -

Gross Profit

45.7 M 48.8 M 16.9 M 39.5 M 17.1 M -61.2 M - - - - - - - - -

Operating Income

-86.4 M -74.4 M -146 M -193 M -193 M -162 M -102 M - - - - - - - -

Interest Expense

2.77 M -13 K -2 K 98 K 651 K 1.14 M -96 K - - - - - - - -

EBITDA

-79.7 M -65.5 M -137 M -187 M -191 M -160 M - - - - - - - - -

Operating Expenses

132 M 123 M 162 M 232 M 210 M 100 M - - - - - - - - -

General and Administrative Expenses

39.2 M 39.8 M 49.6 M 77.6 M 85.7 M 24.4 M - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Butterfly Network

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

262 M 257 M 252 M 248 M 235 M 213 M 212 M 209 M 207 M 205 M 203 M - 200 M 199 M 199 M - 196 M 192 M 106 M - 6.07 M 6.03 M 5.98 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-12.9 M -12.7 M -34 M -13.8 M -14 M -16.9 M -15.7 M -21.8 M -27.4 M -28.7 M -33.5 M - -54.7 M -35.8 M -44.5 M - -13.6 M -2.94 M -690 K - -92.2 M -23.2 M -24.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

32.6 M 26.5 M 21.5 M 23.4 M 21.2 M 20.6 M 21.5 M 17.7 M 15.4 M 18.5 M 15.5 M - 19.6 M 19.2 M 15.6 M - 14.6 M 16.5 M 12.4 M - 10.1 M 11.8 M 8.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

9.32 M 8.24 M 25.2 M 8.49 M 7.84 M 8.33 M 8.9 M 7.38 M 6.04 M 7.56 M 6.39 M - 8.63 M 8.64 M 7.23 M - 19.7 M 8.29 M 6.03 M - 79.4 M 11.6 M 9.51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

23.3 M 18.3 M -3.76 M 14.9 M 13.4 M 12.2 M 12.6 M 10.3 M 9.38 M 10.9 M 9.09 M - 11 M 10.6 M 8.34 M - -5.12 M 8.22 M 6.42 M - -69.3 M 165 K -836 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-13.7 M -13.9 M -35.1 M -16.1 M -18.5 M -17.2 M -17.2 M -22.6 M -32.6 M -31.3 M -35 M - -46 M -48.5 M -49.5 M - -57 M -36.7 M -53.7 M - -91.8 M -23.1 M -24.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-43 K -124 K -86 K 531 K 2.38 M 717 K -59 K -141 K -217 K -60 K 17 K - 2 K -388 K -100 K - 645 K 7 K 638 K - 300 K 113 K 5 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-13.7 M -13.9 M -35.1 M -16.1 M -18.5 M - - - - - -32.9 M - -42 M -48.5 M -48.7 M - -55.6 M -36.7 M -53.3 M - -90.9 M -22.5 M -24.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

37 M 32.2 M 31.4 M 31 M 31.8 M 29.5 M 29.8 M 32.9 M 41.9 M 42.2 M 44.1 M - 57 M 59 M 57.9 M - 51.9 M 44.9 M 60.2 M - 22.6 M 23.2 M 23.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.4 M 10.8 M 9.29 M 9.13 M 9.6 M 9.35 M 10.1 M 10.4 M 11.6 M 14.7 M 11 M - 16.6 M 18.7 M 18.8 M - 16 M 17.3 M 34.6 M - 5.07 M 5.34 M 5.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Butterfly Network (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Myomo Myomo
MYO
$ 1.01 1.0 % $ 42.3 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
InspireMD InspireMD
NSPR
$ 0.65 -3.68 % $ 41.8 M israelIsrael
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.38 1.79 % $ 223 M canadaCanada
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.48 -1.14 % $ 148 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.4 -2.0 % $ 123 M australiaAustralia
AxoGen AxoGen
AXGN
$ 42.21 2.08 % $ 1.94 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 62.84 -2.33 % $ 9.54 B usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 31.56 -2.46 % $ 27.4 B britainBritain
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 28.17 -0.11 % $ 644 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.73 2.83 % $ 34.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.5 2.58 % $ 1.33 B usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.67 -0.77 % $ 454 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.94 2.47 % $ 423 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 11.19 1.08 % $ 463 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Inogen Inogen
INGN
$ 6.45 0.47 % $ 172 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.36 3.08 % $ 22.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.82 -1.39 % $ 13.9 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 121.21 20.18 % $ 4.21 B usaUSA
Beyond Air Beyond Air
XAIR
$ 5.28 -2.68 % $ 43.8 B usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 -0.6 % $ 60 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.14 -1.12 % $ 4.37 B britainBritain
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA